ArticleBMJ open2024

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial.

Stefan Stewart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.